|
|
| |
| |
 |
Dr. Chandra Verma
Principal Investigator
Details |
| |
| |
| Group Members |
| |
| Name | Title |
|---|
| Dr. VERMA Chandra | Principal Investigator |
| Dr. FUENTES Gloria | Assistant Principal Investigator |
| Dr. JOSEPH Thomas Leonard | Research Scientist |
| Dr. LI Jianguo |
Postdoctoral Fellow - SERI |
| Dr. DILRAJ Lama | Postdoctoral Fellow |
| Dr. GAN Ken En Samuel | Postdoctoral Fellow |
| Dr. Suryani LUKMAN | Postdoctoral Fellow |
| Mr. ZHOU Weizhuang | Research Officer |
| Mr. TAN Yaw Sing |
PhD Student |
| Ms. Zahra OUARAY |
PhD student |
|
| |
Research Overview
A combination of homology modeling, electrostatic analyses, molecular dynamics simulations, normal mode analyses, reaction path methods and virtual screening through filtering and docking are used to understand the nature of proteins and their interactions with other proteins, nucleic acids or small molecules. The work builds upon foundations that are rooted in rigorous computational biochemistry benchmarked extensively against available experimental data (see for example previous work at http://www.ysbl.york.ac.uk/~chandra/reaction1.html & http://www.ysbl.york.ac.uk/~chandra/reaction2.html), and is now extended to problems that address biological issues. In particular we combine simulations with detailed experimental information to provide incisive insights into biology at an atomic level (EMBO Reports 9:144; 2008).
Our current research focus is on the p53 pathway, kinases, translation initiation, cyclins, defensins and basic structural/computational biophysical chemistry.
|
| |
| More Details |
| |
|
| |
| Selected Publications |
| |
- Brown CJ, Dastidar SG, Quah ST, Lim A, Chia B, Verma CS.
C-terminal substitution of MDM2 interacting peptides modulates binding affinity by distinctive mechanisms.
PLoS One. 2011;6(8):e24122.
PMID:21904608
- Fuentes G, Scaltriti M, Baselga J, Verma CS.
Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism.
Breast Cancer Res. 2011 13(3):R54.
PMID:21600050
- Goudie DR, D'Alessandro M, Merriman B, Lee H, Szeverényi I, Avery S, O'Connor BD, Nelson SF, Coats SE, Stewart A, Christie L, Pichert G, Friedel J, Hayes I, Burrows N, Whittaker S, Gerdes AM, Broesby-Olsen S, Ferguson-Smith MA, Verma C, Lunny DP, Reversade B, Lane EB.
Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1.
Nat Genet. 2011 43(4):365-9.
PMID:21358634
- Dastidar SG, Raghunathan D, Nicholson J, Hupp TR, Lane DP, Verma CS.
Chemical states of the N-terminal "lid" of MDM2 regulate p53 binding: simulations reveal complexities of modulation.
Cell Cycle. 2011 10(1):82-9.
PMID:21191186
- Brown CJ, Lim JJ, Leonard T, Lim HC, Chia CS, Verma CS, Lane DP.
Stabilizing the eIF4G1 ?-helix increases its binding affinity with eIF4E: implications for peptidomimetic design strategies.
J Mol Biol. 2011 405(3):736-53.
PMID:21094167
- Joseph TL, Lane D, Verma CS.
Stapled peptides in the p53 pathway: computer simulations reveal novel interactions of the staples with the target protein.
Cell Cycle. 2010 9(22):4560-8.
PMID:21088491
- Cheok CF, Verma CS, Baselga J, Lane DP.
Translating p53 into the clinic.
Nat Rev Clin Oncol. 2011 8(1):25-37.
PMID:20975744
- Ng YW, Raghunathan D, Chan PM, Baskaran Y, Smith DJ, Lee CH, Verma C, Manser E.
Why an A-loop phospho-mimetic fails to activate PAK1: understanding an inaccessible kinase state by molecular dynamics simulations.
Structure. 2010 18(7):879-90.
PMID:20637424
- Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, Smith DJ, Landolfi S, Ramon y Cajal S, Arribas J, Baselga J.
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.
Oncogene. 2009 28(6):803-14.
PMID:19060928
- Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP.
Awakening guardian angels: drugging the p53 pathway.
Nat Rev Cancer. 2009 9(12):862-73.
PMID:19935675
|
|
|
